Atezolizumab and Stereotactic Body Radiation Therapy in Metastatic, Recurrent or Persistent Cervical Cancer: Interim Results from a Non-Randomized, Open-Label Phase II Multi-Institutional Study

Ahmed, Kamran A.; Quick, A.M.; Bixel, K.; Kim, Y.; Lemerond, E.; Chon, H.S.; Chern, J.Y.; Fernandez, D.C.; Hoffman, M.S.; Kim, S.; Lam, C.; Montejo, M.E.; Shahzad, M.M.; Wenham, R.M.

doi:10.1016/j.ijrobp.2022.07.501

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Atezolizumab and Stereotactic Body Radiation Therapy in Metastatic, Recurrent or Persistent Cervical Cancer: Interim Results from a Non-Randomized, Open-Label Phase II Multi-Institutional Study

Cited by 3 publications

References 0 publications

Molecular Target Drug for Cervical Cancer

Molecular Target Drug for Cervical Cancer

Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?

Response to Alexandre Andre B A da Costa et al.

Contact Info

Product

Resources

About